Pre-operative Chemotherapy Versus Concurrent Chemoradiotherapy in Locally Advanced Non-small Cell Lung Cancer

• Status: Unknown status
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This phase II trial is to compare neoadjuvant chemotherapy with concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer (NSCLC) to address optimal induction strategy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The First Affiliated Hospital of Guangzhou Medical University
• Treatments: Carboplatin; Docetaxel

Criteria

Inclusion Criteria:

• Histopathologic diagnosis of non small-cell lung cancer

• Clinical stage IIIA and/or IIIB without pleural effusion

• ECOG functional status 0 or 1

• No renal function alteration (GFR >50%)

• No hepatic function alteration (ALT and AST less than 2 times its normal value)

• Leucocytes more than 2,000/mcl

• Hemoglobin more than 10mg/dL

• Platelets more than 100,000/mcl

Exclusion Criteria:

• Active uncontrolled infection.

• Serious concomitant disorders that would compromise the safety of patient or compromise the patient's ability to tolerate therapy.

• MI within preceding 6 months or symptomatic heart disease including unstable angina, congestive heart failure, or uncontrolled arrhythmia.

• Significant neurological or mental disorder.

• Second primary malignancy.

• Pregnant or nursing.